Clinical Trials
51
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
Momelotinib in VEXAS Syndrome
- Conditions
- VEXAS SyndomeMyelo Dysplastic Syndrome
- Interventions
- Drug: Momelotinib treatment
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 57
- Registration Number
- NCT07098936
- Locations
- 🇫🇷
CHU d'Angers - Service des Maladies du sang, Angers, France
🇫🇷CHU Estaing - Service d'Hématologie Clinique, Clermont-Ferrand, France
🇫🇷Hôpital Claude Huriez - Service de Médecine Interne, Lille, France
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, Acute
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 6990
- Registration Number
- NCT06956755
- Locations
- 🇫🇷
Aspasia Stamatoullas, Rouen, France
Oral arsenic (ATO) in low-risk myelodysplastic syndromes (MDS) failing Erythropoiesis Stimulating Agents and Luspatercept
- Conditions
- low-risk Myelodysplastic Syndromes failing Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter)
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Groupe Francophone Des Myelodysplasies
- Target Recruit Count
- 24
- Registration Number
- 2024-515311-22-00
- Locations
- 🇫🇷
CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique, Nice, France
🇫🇷Hôpital Saint Louis - Service Hématologie séniors, Paris, France
🇫🇷Institut Gustave Roussy - Service d'hématologie, Villejuif, France
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 36
- Registration Number
- NCT05782127
- Locations
- 🇫🇷
Hôpital privé Sévigné, Cesson Sévigné, France
🇫🇷CHU d'Amiens Picardie - Site sud, Amiens, France
🇫🇷CHU d'Angers, Angers, France
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 44
- Registration Number
- NCT05768711
- Locations
- 🇫🇷
Hôpital Claude Huriez, Lille, France
🇫🇷Hôpital NOVO, Pontoise, France
🇫🇷CHU d'Amiens, Amiens, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next